Janux Therapeutics, Inc. (JANX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Unaudited Condensed Financial Statements for the quarterly period ended March 31, 2026. Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and autoimmune diseases using its proprietary TRACTr, TRACIr, and ARM platforms. The company has no product revenue and relies on collaboration agreements and capital markets for funding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $3.7 million | $0 |
| Net Loss | $(24.4) million | $(23.5) million |
| Loss Per Share (Basic & Diluted) | $(0.39) | $(0.38) |
| Operating Expenses | $37.9 million | $34.9 million |
| Cash, Cash Equivalents & Short-Term Investments | $956.4 million | $966.6 million (Dec 31, 2025) |
| Accumulated Deficit | $(375.7) million | $(261.3) million (Mar 31, 2025) |
| Net Cash Used in Operating Activities | $(12.3) million | $(17.0) million |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $3.7 million in collaboration revenue in Q1 2026, compared to zero in Q1 2025. This is attributable to a new exclusive license and collaboration agreement with Bristol-Myers Squibb (BMS) entered into in January 2026.
- Operating Expenses: Total operating expenses increased by $3.0 million (8.7%) year-over-year. Research and Development (R&D) expenses rose by $1.8 million, driven by increased preclinical program costs and development of the lead candidate JANX007. General and Administrative (G&A) expenses increased by $1.3 million due to higher consulting and personnel costs.
- Deferred Revenue: Current deferred revenue increased significantly to $37.6 million (up from $0 in Q4 2025) due to the upfront and milestone payments received under the BMS agreement.
- Accounts Receivable: Accounts receivable increased to $35.0 million, primarily related to the BMS developmental milestone payment achieved in March 2026.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($956.4 million) are sufficient to fund operations for at least the next 12 months.
- Collaboration Agreements:
- BMS Agreement: Received a $15.0 million upfront payment and a $35.0 million developmental milestone payment in March 2026. Eligible for up to $750.0 million in additional milestones and tiered royalties.
- Merck Agreement: No revenue recognized in Q1 2026 as performance obligations for both collaboration targets were completed in prior periods.
- Development Updates:
- JANX007: Lead candidate in Phase 1 for metastatic castration-resistant prostate cancer (mCRPC).
- JANX014: Entered clinical evaluation in April 2026.
- JANX011: Phase 1 study initiated in February 2026 for autoimmune diseases.
- JANX008: Voluntarily discontinued in April 2026 following Phase 1a review due to insufficient activity magnitude.
- Risks: The company faces standard biotech risks including clinical trial failure, regulatory delays, and the need for future capital raises. Specific risks include reliance on third-party manufacturers (including WuXi Biologics in China) and potential trade restrictions.
Investor Verification Checklist
- Verify the timing of revenue recognition for the BMS agreement and the specific milestones triggering the $35.0 million payment.
- Confirm the burn rate and cash runway given the $12.3 million net cash used in operating activities for the quarter.
- Review the status of the discontinued JANX008 program and its impact on future R&D expense projections.
- Assess the concentration risk regarding the single customer (BMS) for all Q1 2026 revenue and accounts receivable.
- Monitor the progress of the Phase 1 trials for JANX007, JANX011, and JANX014 as the primary drivers of future value.